Drug intelligence / Profile preview

CMM2-KLH-DC vaccine

Development stage: Preclinical
Lead developer: Nippon Veterinary and Life Science University
Modality: Vaccines & Immunotherapeutics, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
Administration: Intradermal, Intranodal, Intraperitoneal, Subcutaneous, Intratumoral

Overview

The CMM2-KLH-DC vaccine is a dendritic cell-based vaccine developed for the treatment of canine malignant melanoma. It utilizes autologous dendritic cells (DC) that are pulsed in vitro with canine melanoma CMM2 cell lysate and keyhole limpet haemocyanin (KLH). The vaccine is designed to induce T cell-mediated immune responses against CMM2 cells in vivo, as evidenced by delayed-type hypersensitivity (DTH) skin tests showing recruitment of CD8 and CD4 T cells to positively responding sites. This approach aims to leverage the immune system to target and eliminate melanoma cells in dogs.

Beyond the preview

Go deeper on CMM2-KLH-DC vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CMM2-KLH-DC vaccine.

Explore the full profile